论文部分内容阅读
目的研究孟鲁司特对哮喘急性发作期外周血炎症因子的影响。方法选择2015年12月至2016年3月接受治疗的70例哮喘急性发作期患者为研究对象,将其随机分为两组,35例常规组患者仅实施常规治疗,35例研究组患者在采取上述治疗措施的同时使用孟鲁司特进行治疗,比较分析两组临床效果。结果治疗前,两组患者外周血干扰素-γ(IFN-γ)、白细胞介素-4(IL-4)水平较接近,组间对比差异未见统计学意义(P>0.05);治疗后两组患者IFN-γ、IL-4水平均有所改善,而且研究组改善情况明显优于常规组,组间对比差异有统计学意义(P<0.05)。常规组治疗总有效率为84%,研究组为96%,两组比较差异有统计学意义(P<0.05)。常规组不良反应发生率为8.57%,研究组为5.71%,两组比较差异未见统计学意义(P>0.05)。结论哮喘急性发作期患者给予孟鲁司特治疗能够有效缓解症状,提高治疗效果,促进外周血炎性因子平衡,在临床上有较大推广使用价值。
Objective To study the effect of montelukast on peripheral blood inflammatory factors during acute exacerbation of asthma. Methods Seventy patients with acute exacerbation of asthma who were treated from December 2015 to March 2016 were selected and randomly divided into two groups. 35 patients in routine group were treated only routinely, 35 patients in study group were taken The treatment of montelukast treatment at the same time, a comparative analysis of the clinical effects of both groups. Results Before treatment, the levels of IFN-γ and IL-4 in the two groups were similar, but there was no significant difference between the two groups (P> 0.05). After treatment The levels of IFN-γ and IL-4 in both groups were improved, and the improvement in the study group was significantly better than that in the conventional group. The difference between the two groups was statistically significant (P <0.05). The total effective rate of conventional treatment group was 84%, the study group was 96%, the difference between the two groups was statistically significant (P <0.05). The incidence of adverse reactions was 8.57% in the conventional group and 5.71% in the study group, with no significant difference between the two groups (P> 0.05). Conclusion Montelukast treatment can effectively relieve symptoms, improve the therapeutic effect and promote the balance of inflammatory factors in peripheral blood in the patients with acute exacerbation of asthma. It is of great value in clinical application.